TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12833110

Group type: EXPERIMENTAL
Intervention: Physical Activity Level (PAL)
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Dietary energy intake
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Dietary Calcium intake
Number of subjects: 1064
Study: 11469292

Group type: EXPERIMENTAL
Intervention: CO2 laser (10.600 nm)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1.064 nm)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ArF excimer laser (193 nm)
Number of subjects: 66
Study: 9034644

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serotonin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ergonovine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetylcholine and Serotonin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serotonin but not Acetylcholine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetylcholine but not Serotonin
Number of subjects: 20
Study: 8366188

Group type: EXPERIMENTAL
Intervention: famotidine 2.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: famotidine 5.0 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: famotidine 10.0 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: famotidine 0.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 2901062

Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study: 30276974

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and cisplatin
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy with intensity-modulated radiation of 50 Gy
Number of subjects: 486

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 486
Study: 27483185

Group type: EXPERIMENTAL
Intervention: Safer sex intervention delivered via automated mobile phone messaging over 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Monthly text message checking contact details (Control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Safer sex intervention delivered via automated mobile phone messaging
Number of subjects: 200
Study: 24091560

Group type: EXPERIMENTAL
Intervention: Tap water nasal irrigation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-tap water nasal irrigation
Number of subjects: 64
Study: 23404880

Group type: EXPERIMENTAL
Intervention: Layered stimulus and response training (LSRT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) practice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visual imagery (VI) practice
Number of subjects: 24
Study: 15829782

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection into the mid-belly of the muscle bulks (distal group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Botulinum toxin A injection into the proximal part of both heads of the gastrocnemius (proximal group)
Number of subjects: 19
Study: 12810404

Group type: EXPERIMENTAL
Intervention: MLCT diet (14 g of MLCT containing 1.7 g MCFA daily at breakfast for 12 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: LCT diet (control group)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MLCT diet
Number of subjects: 82
Study: 9795914

Group type: EXPERIMENTAL
Intervention: 25 mg lamivudine once daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 100 mg lamivudine once daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine once daily
Number of subjects: 51
Study: 8535683

Group type: EXPERIMENTAL
Intervention: Transurethral hyperthermia (TUH)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transurethral sham (TUS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transrectal hyperthermia (TRH)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transrectal sham (TRS)
Number of subjects: 200
Study: 2227221

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Propranolol 40 mg three times daily
Number of subjects: 26
Study: 83330

Group type: EXPERIMENTAL
Intervention: Rapid smoking (overt aversion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Covert sensitization (symbolic aversion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of rapid smoking and covert sensitization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 31511232

Group type: EXPERIMENTAL
Intervention: Running programme intervention
Number of subjects: 3040

Group type: EXPERIMENTAL
Intervention: Shoe-related intervention
Number of subjects: 3040
Study: 29492784

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 26
Study: 27895298

Group type: EXPERIMENTAL
Intervention: Right insular involvement
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Left insular involvement
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Mild/moderate strokes with right insular involvement
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Severe strokes with right insular involvement
Number of subjects: 2099
Study: 24172309

Group type: EXPERIMENTAL
Intervention: 20 g MCT oil/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: 20 g corn oil/d
Number of subjects: 28
Study: 22020134

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-rich fish oil (1g)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-rich fish oil (2g)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 65
Study: 20434660

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 113

Group type: COMPARATOR
Intervention: Double-bundle ACL reconstruction
Number of subjects: 113
Study: 19014838

Group type: EXPERIMENTAL
Intervention: Test formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Test formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Number of subjects: 38
Study: 16047460

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 10
Study: 12518705

Group type: EXPERIMENTAL
Intervention: Autologous bone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bio‐Oss
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (nonaugmented sites)
Number of subjects: 18
Study: 10363292

Group type: EXPERIMENTAL
Intervention: BASC Parent Rating Scale (PRS) 6‐11, authorized Spanish version
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BASC PRS (6‐11)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cluster analysis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total sample assessment
Number of subjects: 120
Study: 9381885

Group type: EXPERIMENTAL
Intervention: Intravaginal application of 'Zhlemik' on a tampon
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal suppositories of 'Zhlemik'
Number of subjects: 40
Study: 2210463

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Cimetidine (400 mg four times daily)
Number of subjects: 270
Study: 7004258

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31751759

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for hazelnut allergy for at least 6 months.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline eliciting dose of hazelnut protein was 106 mg (IQR, 51-249); after 6 months of OIT, it increased to 523 mg (IQR, 190-1635) (P < .0001).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OIT
Number of subjects: 100
Study: 30341774

Group type: EXPERIMENTAL
Intervention: Topical regorafenib (25 μl, 30 mg ml‐1) three times a day for 12 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ocular treatment‐emergent adverse events (TEAEs)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rescue treatment (intravitreal ranibizumab)
Number of subjects: 51
Study: 28811738

Group type: EXPERIMENTAL
Intervention: Behavioral intervention with partner enrollment
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for obese participants
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for morbidly obese participants
Number of subjects: 238
Study: 25802037

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) for 12 weeks (three weekly sessions lasting 38 min with ≈ 16 min at 85‐90% of VO2peak)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low energy diet (LED, 800‐1000 kcal/day) for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low energy diet (LED)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both AIT and LED
Number of subjects: 70
Study: 24058667

Group type: EXPERIMENTAL
Intervention: Expert video game players (VGPs)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-video game players (non-VGPs)
Number of subjects: 31
Study: 21383284

Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid chemotherapy
Number of subjects: 1913

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 1913
Study: 19263118

Group type: EXPERIMENTAL
Intervention: Torsional mode ultrasonically activated device (TM)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Linear mode ultrasonically activated device (LM)
Number of subjects: 151
Study: 17255220

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin suppository (DHA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular artemether (ART)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both DHA and ART
Number of subjects: 60
Study: 15472673

Group type: EXPERIMENTAL
Intervention: 3 doses of aqueous sodium phosphate (45 mL each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 doses of aqueous sodium phosphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 doses of aqueous sodium phosphate
Number of subjects: 0
Study: 11486720

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 9551878

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 8038733

Group type: EXPERIMENTAL
Intervention: Exposure to a live harmless snake
Number of subjects: 224
Study: 2647472

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 32
Study: 30012268

Group type: EXPERIMENTAL
Intervention: Atole (protein-energy nutritional supplementation) from conception to age 2 years
Number of subjects: 1661
Study: 28965562

Group type: EXPERIMENTAL
Intervention: 150g cod
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 150g salmon
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 150g blue mussels
Number of subjects: 38

Group type: COMPARATOR
Intervention: potato (control)
Number of subjects: 38
Study: 26485846

Group type: EXPERIMENTAL
Intervention: Peri-prostatic local infiltration anesthesia (PLIA) alone (G1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Combined topical anal lignocaine ointment and local infiltration anesthesia (G2)
Number of subjects: 163
Study: 23211715

Group type: EXPERIMENTAL
Intervention: Optimal supportive care + whole brain radiotherapy (WBRT) (20 Gy in five fractions)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Optimal supportive care (OSC)
Number of subjects: 151
Study: 21986329

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon followed by bare metal stent (DCB first)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bare metal stent followed by paclitaxel-coated balloon (BMS first)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bare metal stent first
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon first
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study: 18467648

Group type: EXPERIMENTAL
Intervention: Therapist-assisted locomotor training (LT) for 12 sessions of 30 minutes each
Number of subjects: 48

Group type: COMPARATOR
Intervention: Robotic-assisted locomotor training (LT) for 12 sessions of 30 minutes each
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Therapist-assisted LT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Robotic-assisted LT
Number of subjects: 48
Study: 17139644

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage plus administration of corticosteroids (ALC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Joint aspiration plus administration of corticosteroids (JAC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Arthroscopic lavage plus administration of placebo (ALP)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High synovial extent of fibrosis after ALC
Number of subjects: 78
Study: 12699175

Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized ablation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 20
Study: 10750366

Group type: EXPERIMENTAL
Intervention: Argatroban (10 mg intravenous drip infusion)
Number of subjects: 14
Study: 8997865

Group type: EXPERIMENTAL
Intervention: Permethrin impregnated sisal curtains
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 523
Study: 1630802

Group type: EXPERIMENTAL
Intervention: Anti-HCV antibody positive patients in chronic haemodialysis
Number of subjects: 155

Group type: COMPARATOR
Intervention: Polytransfused group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Patients with HBV and/or HCV infection
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Screening for HBV and HCV markers
Number of subjects: 155
Study: 6203818

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 50
Study: 30573517

Group type: EXPERIMENTAL
Intervention: Dietary intervention (three 8-day periods)
Number of subjects: 24
Study: 28960146

Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 324

Group type: COMPARATOR
Intervention: Non-alcoholic beverage cues
Number of subjects: 324
Study: 27000327

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Non-canagliflozin (control)
Number of subjects: 183
Study: 23473519

Group type: EXPERIMENTAL
Intervention: Air insufflation via a subglottic catheter
Number of subjects: 14

Group type: COMPARATOR
Intervention: No air insufflation
Number of subjects: 14
Study: 22789789

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 123
Study: 20007979

Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 0
Study: 17644412

Group type: EXPERIMENTAL
Intervention: Non-invasive screening tests for post-MI patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More conservative ICD programming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual chamber minimal ventricular pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg of KW-3902 (selective A1 adenosine receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canrenone
Number of subjects: 0
Study: 16326292

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion plus 10 microg/kg of intrathecal morphine (ITM group, n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Remifentanil infusion alone (control group, n = 23)
Number of subjects: 46
Study: 12003472

Group type: EXPERIMENTAL
Intervention: High-power groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-power groups
Number of subjects: 0
Study: 9817281

Group type: EXPERIMENTAL
Intervention: Standard-dose m-BACOD plus GM-CSF
Number of subjects: 192
Study: 7807297

Group type: EXPERIMENTAL
Intervention: Patients with consecutive esotropia (postoperative)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control patients (maintained fusion)
Number of subjects: 21
Study: 2571009

Group type: EXPERIMENTAL
Intervention: Advice on fatty fish intake
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Advice on fat intake
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Advice on fibre intake
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Dietary regimens overall
Number of subjects: 2033
Study: 819200

Group type: COMPARATOR
Intervention: Treatment in air with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment in hyperbaric oxygen (3 atm) with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cumulative Radiation Effect (CRE) analysis of treatment regimes.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CRE level of 1910 reu.
Number of subjects: 27
Study: 7407482

Group type: EXPERIMENTAL
Intervention: D-propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study: 28715932

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce physical disability
Number of subjects: 147
Study: 30123250

Group type: EXPERIMENTAL
Intervention: Action Observation Treatment (AOT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 26377235

Group type: EXPERIMENTAL
Intervention: SHAPe curriculum (intervention group, n=500)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Control group (n=498)
Number of subjects: 998
Study: 24983542

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study: 22863021

Group type: EXPERIMENTAL
Intervention: Rapid Syllable Transition Treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nuffield Dyspraxia Programme - Third edition
Number of subjects: 20
Study: 19602554

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Growth Hormone + Testosterone (GH+T)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Testosterone (T)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 131
Study: 17617776

Group type: EXPERIMENTAL
Intervention: Long distance corridor walk (LDCW) time
Number of subjects: 492
Study: 15117375

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/clindamycin topical gel (5% benzoyl peroxide and 1% clindamycin)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/clindamycin topical gel
Number of subjects: 53
Study: 12478408

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g t.i.d.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (2 g q.i.d.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 38
Study: 9699819

Group type: EXPERIMENTAL
Intervention: Harris hip score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile
Number of subjects: 100
Study: 8012963

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at 3.9 mg/kg and Ciprofloxacin (Cipro) 500 mg p.o. every 12 h on days 1-5 and 10-20.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Historical control patients receiving IL-2/LAK without PTX/Cipro.
Number of subjects: 18
Study: 2595345

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Piroxicam 20 mg daily
Number of subjects: 10
Study: 785689

Group type: EXPERIMENTAL
Intervention: 12 hours of urokinase
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: 24 hours of urokinase
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: 24 hours of streptokinase
Number of subjects: 327

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 327
Study: 31270506

Group type: EXPERIMENTAL
Intervention: Wild-type S. Typhi
Number of subjects: 40

Group type: COMPARATOR
Intervention: Typhoid toxin deletion mutant (TN) S. Typhi
Number of subjects: 40
Study: 28028737

Group type: EXPERIMENTAL
Intervention: 1-month sustained-release triptorelin
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: 3-month sustained-release triptorelin
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: 6-month sustained-release triptorelin
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: 9-month sustained-release triptorelin
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: 12-month sustained-release triptorelin
Number of subjects: 920
Study: 26081833

Group type: EXPERIMENTAL
Intervention: Ipas MVA plus (MVA), n = 122
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wallach Endocell (Endocell), n = 118
Number of subjects: 240
Study: 23370795

Group type: EXPERIMENTAL
Intervention: 0.1 mg/70 kg i.v. buprenorphine in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg i.v. buprenorphine in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg i.v. buprenorphine in rats
Number of subjects: 0